METiS Therapeutics utilizes artificial intelligence, machine learning, and molecular dynamics to develop targeted delivery systems for small molecules and gene therapies. The company addresses the challenge of efficient drug delivery by creating lipid nanoparticles that demonstrate high delivery efficiency and safety profiles across multiple organ systems.
Funding
$75M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Effective drug delivery remains a significant hurdle in treating many diseases, as traditional methods often lack the precision to target specific tissues or cells, leading to systemic side effects and reduced therapeutic efficacy. Developing targeted delivery systems that can navigate biological barriers and release drugs at the intended site of action is a complex challenge.
Solution
METiS Therapeutics is developing a platform for AI-driven drug discovery and targeted delivery of small molecules, biologics, and nucleic acid therapies. The company uses artificial intelligence (AI), machine learning (ML), and molecular dynamics (MD) to design novel lipid nanoparticles (LNPs) with enhanced targeting capabilities. Their approach involves high-throughput in vivo screening, guided by AI, to identify LNPs that exhibit high delivery efficiency and favorable safety profiles across multiple organ systems. This technology aims to improve drug bioavailability, reduce off-target effects, and enable the development of more effective treatments for a range of diseases.
Target Audience
METiS Therapeutics primarily targets pharmaceutical companies and research institutions seeking advanced drug delivery technologies and novel therapeutic candidates.
Features
- AI-driven LNP design using machine learning and molecular dynamics simulations
- High-throughput in vivo screening platform for identifying optimal LNP candidates
- Targeted delivery to multiple organ systems, demonstrated in murine and non-human primate models
- Enhanced drug bioavailability and reduced off-target effects
- Development of novel therapeutics in small molecule, biologics, and nucleic acid spaces